Childhood absence epilepsy (CAE) is one of the most frequent epilepsies in infancy. The first-line recommended therapy for CAE is based on the prescription of the narrow-spectrum ethosuximide and the broad-spectrum valproic acid, which have similar efficacy in the first 12 months. Nevertheless, some antiepileptic drugs (AEDs) may worsen seizure duration and type in this syndrome. In line with this, we have encountered a case of identical twins with CAE and early exposure to different antiseizure drugs leading to divergent outcomes. From this, we hypothesized that the first AED to treat CAE may determine the long-term prognosis, especially in the developing brain, and that some situations leading to drug resistance may be explained by use of an inappropriate first AED. Therefore, we investigated this hypothesis by using a genetic mouse model of absence epilepsy (BS/Orl). Mice received a first appropriate or inappropriate AED followed by the same appropriate AED. Our data demonstrate that an inappropriate first AED has a negative impact on the long-term efficacy of a second appropriate AED. This work supports the necessity to effectively diagnose epileptic syndromes prior to medication use, particularly in children, in order to prevent the deleterious effects of an inappropriate initial AED.
| INTRODUCTION
Childhood absence epilepsy (CAE) has a prevalence of 7 in every 10 000 children and is one of the most frequent epilepsies in infancy. 1 Classically this epilepsy begins between 4 and 10 years of age with many absence seizures (AS) a day, as defined as an abrupt behavior arrest with a loss of consciousness concomitant to ictal electroencephalography (EEG) discharges of 3 Hz generalized spike and waves, bilateral and symmetric discharges (SWDs). 2 The first-line recommended therapy is based on the prescription of the narrow-spectrum ethosuximide (ESM) and the broad-spectrum valproic acid (VPA) which have similar efficacy in the first 12 months with 45% freedomfrom-failure rate, including intolerable adverse effects and lack of seizure control, in particular. 3 Nevertheless, some antiepileptic drugs (AEDs) such as carbamazepine (CBZ) and vigabatrin (VGB) may worsen seizure duration and clinical type in this syndrome (ie, generalized tonic-clonic seizures can occur) and could alter the prognosis. [4] [5] [6] Fortuitously, we have been faced with a case of identical twins with CAE and early exposure to different antiseizure drugs leading to divergent outcomes. GB started with the first AS at age 6 (1986 Because these twins were initially treated with different AEDs, we hypothesized that the diverging outcomes are the result of a first unsuccessful AED, which determines the efficacy of subsequent AEDs. Overall, this example sheds light on the hypothesis that we address, suggesting that a first medication to treat epilepsy could have an effect on the long-term prognosis, especially in the developing brain. Hence, a poor first treatment can be responsible for a deleterious long-term outcome. To test this hypothesis we used a validated mouse model of absence epilepsy (BS/Orl), where outcomes were compared in mice receiving a different appropriate or inappropriate initial AED for absence epilepsy followed by a common, appropriate AED for this form of epilepsy. Here we use appropriate to refer to generally effective and commonly used medication for CAE.
| METHODS
To investigate the long-term impact of a first AED treatment on the evolution of seizures after subsequent AEDs, we studied 4 groups of male BS/Orl mice, a genetic model for absence epilepsy presenting spontaneous SWD, 7 which received various initial AED treatments followed by a common AED. The care and experimental manipulation of the animals were carried out in accordance with the guidelines of the European Union (directive 2010/63/EU). At 25 AE 2 days of age, male BS/Orl mice were implanted under general anesthesia (chloral hydrate, 400 mg/kg, ip) with 4 monopolar tungsten rod electrodes placed bilaterally over the frontal and parietal cortex and 1 electrode placed over the cerebellum as a reference electrode. All electrodes were connected to a female microconnector and fixed to the skull with cyanoacrylate and acrylic cement. One week after implantation, and every 2 weeks after the start of treatment, freely moving mice were recorded for 3 consecutive days (3 days 9 1 h EEG recording) for basal epileptic activities using a digital acquisition computer-based system (Coherence, Deltamed, Paris, France, max. 32 acquisition channels -sampling rate 256 Hz) in freely moving animals placed in an acrylic glass cage located in a Faraday cage. Immediately after the first (this initial) EEG recording, mice were treated daily for 2 weeks with either VPA (200 mg/kg/day; Aguettant, Lyon, France, batch number 4202475), ESM (200 mg/kg/day; Sigma-Aldrich France, Saint-Quentin-Fallavier, France, batch number 129K1342), or VGB (500 mg/ kg/day; Sanofi-Aventis, Gentilly, France, batch number 7544) dissolved in saline solution (0.9%). These doses were chosen based on previous research and what is typically used in seizure models and experimental epilepsy in rats as well as in mice. [8] [9] [10] Serum drug levels were not assessed in the present study. All medications were administered daily via an intraperitoneal injection because daily medication use is typical in the clinical situation and also in animal models of absence epilepsy. [8] [9] [10] Thirty minutes prior to EEG measurements, AED administrations were done. After 2 weeks, EEG recordings were undertaken to evaluate the epileptic activity after the first AED treatment; then all mice were treated with only VPA (200 mg/kg/day) for 6 weeks. There was no washout period between drug administrations. EEG recordings were done every 2 weeks. An additional group of male mice only received vehicle (saline solution: PHY). This resulted in 4 groups: (1) PHY-PHY (n = 5), (2) VPA-VPA (n = 5), (3) ESM-VPA (n = 5), and (4) VGB-VPA (n = 4) (Figure 1 ). For all statistical analyses, we used the cumulative duration of SWD activities (CDS), excluding the first 20-min recording which was considered habituation. At baseline, the CDS of the 4 groups of mice were compared using analysis of variance (ANOVA). Then, the variations in the e110 | CDS along the second AED treatment were measured for each EEG using the Response Ratio (RRatio) defined as RRatio ¼
Ã 100, where T EEG 1 is the CDS at baseline and T EEG x at EEG x . RRatios vary from À100 to 100, with À33 corresponding a 50% reduction of the cumulative duration of seizure. At EEG 2 , ANOVAs of the RRatios were used to assess the effect of any treatment versus saline and the differential effect of the first 3 treatments. Finally, a mixed-effect ANOVA for repeated measures of RRatios at EEG 2 to EEG 5 was used. We also compared trajectories using post hoc unilateral or bilateral t-tests, respectively, depending on whether the superiority of one treatment to another to reduce the evolution of the cumulative duration of seizures may be hypothesized or not. Statistical significance was set at P < .05.
| RESULTS
Prior to treatment EEG (EEG 1 ), activity did not differ between groups (F = 2.49, P = .10). After 2 weeks of treatment (EEG 2 ), there was a significant effect of treatment (AEDs vs PHY; F = 10.2, P = .006) and significant differences between treatments (F = 31.70, P < .0001), with ESM treatment being the only AED to show a significant difference in response ratio at EEG 2 (t = 6.91, P < .0001). VPA treatment presents a significantly higher effect than PHY treatment for reducing seizures between EEG2 and EEG5 (t = 1.88, P = .036). At EEG4-EEG5, the initial success of the ESM treatment did not last after VPA treatment compared to the VPA-VPA group (t = 0.51, bilateral P = .63). In addition the negative VGB effect persisted despite a switch to VPA when comparing VGB-VPA and VPA-VPA groups (t = 3.22, unilateral P = .007) and is not significantly different from no treatment, when comparing VGB-VPA and PHY-PHY groups (t = 1.61, bilateral P = .15) (Figure 2 ).
| DISCUSSION
Failure of the first AED to control epilepsies seems to induce (or be a predictor of) a drug resistance, especially in CAE. [11] [12] [13] [14] [15] But as far as we know, whether the outcome could be the consequence of the failure of the initial medication has never been investigated. In the introduction, we reported the case of identical twins with CAE and early exposure to different antiseizure drugs leading to divergent outcomes, which we hypothesized may be due to different initial medications. However, it is interesting to note that the worsening of seizures in the twin who received the "inappropriate" medication did not occur until age 15. We know that the concordance rate in monozygotic twins is high for absence seizures 16, 17 ; therefore it is very likely that both twins had the same disease, presenting as CAE. According to this hypothesis, the obvious factor that led to such a divergent evolution of the disease is represented by the initial antiseizure drug. This could suggest that some antiseizure drugs, when initiated early in the course of the disease, could have a disease-modifying impact, as further studied in our mouse model. However, it is likely that other factors, such as the differences in the age at diagnosis, and the CAE progression, may play a role. In our mouse model, we show that an inappropriate first AED may not be effective and may worsen the epileptic syndrome prognosis when this first inappropriate medication is replaced by an appropriate AED, underlying key effects on brain development. Precisely, we have observed that (1) initial treatment with ESM and VPA have a positive effect on SWD activity, with ESM greatly improving SWD; (2) the benefit obtained in using ESM as a first-line medication compared to VPA is lost when VPA is used instead of, and after, ESM; (3) on the contrary, VPA treatment after VGB did not improve SWD activity at all, such that VGB was as ineffective as no treatment. This study suggests that a form of "acquired drug resistance" can be promoted in CAE by using a first inappropriate treatment. At this stage, one cannot know if the deleterious effect is due to a specific stage in brain development. However, it is clear that the stage of development remains critical, as illustrated by a study realized in a CAE rat model 18 in which an early treatment can definitively suppress the epileptic activity. This finding has obvious implications for clinical practice, since it is well known that the rate of epilepsy misdiagnosis is high, confounding between real epileptic syndromes and nonepileptic seizures. 19 In addition, this finding high- For these 2 reasons, but also because ESM has a greater effect than VPA in our study, our future work will determine the effects of additional medication combinations with a focus on understanding the role that ESM has as a second-line therapy.
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